Overview

Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

Status:
Completed

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

This multicenter, Phase Ib study is an open label, dose escalation, three-arm study evaluating the safety, tolerability, pharmacokinetics, and activity of oral (PO) GDC 0941 administered in combination with either intravenous (IV) infusion of T-DM1 or IV infusion of trastuzumab.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Ado-Trastuzumab Emtansine
Maytansine
Trastuzumab